Mirum Pharmaceuticals (MIRM) announced the completion of enrollment in the Phase 2b VISTAS study of volixibat, an investigational oral IBAT inhibitor, for the treatment of cholestatic pruritus in patients with primary sclerosing cholangitis. The trial previously met its pre-specified efficacy and safety thresholds at the blinded interim analysis for dose selection conducted in 2024 and topline results are expected to be announced in the second quarter of 2026. Volixibat is also being evaluated in the Phase 2b VANTAGE study for primary biliary cholangitis, which is expected to complete enrollment in 2026 and announce topline results in the first half of 2027.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MIRM:
- Mirum Pharmaceuticals’ Volixibat Study: A Potential Game-Changer for PBC Treatment
- Mirum Pharmaceuticals’ Volixibat Study: A Potential Game-Changer for PSC Treatment
- Mirum Pharmaceuticals files automatic mixed securities shelf
- Arm initiated, Adobe downgraded: Wall Street’s top analyst calls
- Mirum Pharmaceuticals resumed with a Buy at Stifel